1. Introduction {#sec1-toxins-10-00042}
===============

Aflatoxin B~1~ (AFB~1~) is a ubiquitous hepatotoxic, hepatocarcinogenic, and immunosuppressive mycotoxin. Poultry and other livestock are exposed to AFB~1~ by consuming contaminated feed. Many agricultural feed commodities (corn, cottonseed, peanuts, and sorghum) and other foods (figs, tree nuts, and spices) are at especially high risk of being contaminated \[[@B1-toxins-10-00042]\]. AFB~1~ is practically unavoidable in most feed ingredients, especially corn \[[@B2-toxins-10-00042],[@B3-toxins-10-00042],[@B4-toxins-10-00042]\], and is expected to concomitantly increase with global climate change \[[@B5-toxins-10-00042]\]. Approximately 25% of the world's annual food supply is contaminated with mycotoxins, and losses attributed to AFB~1~ are significant to the poultry industry \[[@B1-toxins-10-00042]\].

Poultry are among the most sensitive animals to the toxic effects of AFB~1~ \[[@B6-toxins-10-00042],[@B7-toxins-10-00042]\]. Domesticated turkeys are among the most sensitive species \[[@B8-toxins-10-00042]\], but wild turkeys are more resistant \[[@B9-toxins-10-00042]\]. Turkey sensitivity is historically important because it was instrumental in the discovery of AFB~1~ as being responsible for the deaths of domestic turkeys in Europe due to "Turkey X Disease" that was traced to contaminated feed \[[@B10-toxins-10-00042]\]. AFB~1~ is a potent immunotoxin acting to suppress cell-mediated, humoral, and phagocytic functions in chickens and turkeys \[[@B11-toxins-10-00042],[@B12-toxins-10-00042],[@B13-toxins-10-00042]\]. As a result, it has a wide array of toxic effects, including; reduced feed intake, weight gain, and feed efficiency, and increased mortality, hepatotoxicity, GI hemorrhaging, and susceptibility to bacterial and viral diseases. Embryonic exposure to AFB~1~ produces dose-related DNA damage \[[@B14-toxins-10-00042]\] and compromised immune response through suppression of humoral and cellular immunity making hatched chicks more susceptible to disease \[[@B13-toxins-10-00042]\]. Thus, in addition to being a potent natural toxin, AFB~1~ is a powerful "force-multiplier", amplifying adverse effects of other agents that are detrimental to poultry health.

Aflatoxin B~1~ toxicity requires bioactivation by hepatic cytochrome P450s (CYPs) to the electrophilic exo-AFB~1~-8,9-epoxide (AFBO). In the absence of GST activity, AFBO can form adducts that bind to DNA, RNA and other macromolecules, causing immunotoxicity, mutations, and aflatoxicosis \[[@B15-toxins-10-00042]\]. The extreme sensitivity of domesticated turkeys to AFB~1~ is associated with efficient epoxidation by cytochromes P4501A5 and 3A37 \[[@B16-toxins-10-00042]\], both of which have been cloned, heterologously expressed and functionally characterized \[[@B8-toxins-10-00042],[@B17-toxins-10-00042]\]. Using anti-peptide antibodies, P4501A5 was found to be the dominant bioactivating and metabolizing enzyme at environmentally relevant AFB~1~ concentrations in turkey liver \[[@B8-toxins-10-00042]\].

While P450-mediated bioactivation plays an important role, the principal determinant of response to AFB~1~ is the efficiency of detoxification by hepatic glutathione S-transferases (GSTs), most notably alpha class (GSTAs) \[[@B18-toxins-10-00042]\]. The α-GST cluster in turkeys includes six genes, *GSTA1.1*-*A1.3*, *GSTA2*, *GSTA3*, and *GSTA4* \[[@B19-toxins-10-00042],[@B20-toxins-10-00042]\]. Whereas, wild and heritage breed turkeys possess GST-mediated AFBO detoxification activity, livers from domestic turkeys lack detectable activity \[[@B20-toxins-10-00042]\]. Thus, the most likely mechanism for the extreme sensitivity of domestic turkeys is dysfunction in hepatic GSTs, rendering them unable to detoxify AFB~1~ \[[@B21-toxins-10-00042],[@B22-toxins-10-00042],[@B23-toxins-10-00042]\]. As a result, AFBO forms adducts, which can induce DNA mutations, block transcription and alter translation \[[@B24-toxins-10-00042],[@B25-toxins-10-00042]\].

To understand the response of the domesticated turkey to AFB~1~ exposure, we initiated study of the hepatic transcriptome following dietary AFB~1~ challenge. Results of this study identified genes and gene pathways in the liver directly affected by AFB~1~ \[[@B26-toxins-10-00042]\]. Functional analysis found transcripts significantly dis-regulated by toxicity and affecting pathways of cancer, apoptosis, cell cycle, and lipid regulation. These changes reflect the molecular mechanisms of inflammation, proliferation and liver damage in aflatoxicosis. This study was followed by analysis of spleen tissues from the same birds \[[@B27-toxins-10-00042]\] that found short exposure to AFB~1~ suppressed innate immune transcripts, especially from antimicrobial genes that are indicative of either increased cytotoxic potential or activation-induced cell death in the spleen during aflatoxicosis.

To better examine the differences between wild and domesticated birds, we developed an *in ovo* exposure model to provide controlled AFB~1~ exposure to developing embryos \[[@B28-toxins-10-00042]\]. RNA-seq analysis found AFB~1~ effects were dependent on both length of exposure and turkey type (domesticated vs. wild), confirming significant differences in the response to AFB~1~ attributed to genetic background \[[@B28-toxins-10-00042]\]. Transcriptome responses to AFB~1~ occurred more rapidly in domesticated birds (1 day post-exposure), and led to the up regulation in cell cycle regulators, Nrf2-mediated response genes and coagulation factors. Expression changes in the embryonic liver also suggested cellular responses to oxidative stress and xenobiotics were initiated by AFB~1~ exposure. In contrast, the response in wild turkey embryos occurred later (five days post-exposure). Combined, these studies demonstrated that GST-mediated hepatic detoxification of AFBO is largely responsible for the differences in resistance between turkey types, but other processes and pathways (i.e., apoptosis, cellular regulation, immune responses) are also important. Whereas, understanding the effects of AFB~1~ on developing embryos is important in poultry production, the manifestation of AFB~1~ toxicity is likely to be different in more mature birds with fully developed gastrointestinal systems. The purpose of this study was to compare the hepatic transcriptome response to dietary AFB~1~ in juvenile (three weeks of age), susceptible (domesticated), and more resistant (wild) turkeys. We hypothesized that transcriptome responses in juvenile birds would reflect the more mature status of the gastrointestinal and antioxidant systems than those of embryos.

2. Results {#sec2-toxins-10-00042}
==========

Liver measurements were collected at the end of the exposure trial to characterize phenotypic effects of AFB~1~ toxicity. Livers of domesticated (DT) birds (average = 20.54 g) were nearly three times the mass of those from Eastern wild (EW) birds (8.3 g) primarily due to differences in body size (average = 1147.5 g and 396.1 g, respectively). Liver weights of AFB~1~ turkeys were smaller than those of the control (CNTL) groups. In DT, average liver mass at the conclusion of the trial ranged from 14.76 g to 23.98 g in the AFB~1~ group (mean = 20.02 ± 2.44 g) and from 17.39 g to 25.11 g in controls (21.00 ± 2.12 g). Although this difference in liver mass was not significant (*t*-test *p* = 0.1962), when corrected for body weight (% BW) the livers of birds from the AFB~1~-treated group were significantly smaller (*p* = 0.0098). Livers of AFB~1~-treated EW birds (7.19 ± 1.06 g) were similarly smaller than those of control birds (9.43 ± 1.11 g). This difference was significant for absolute mass (*p* = 0.0005) and nearly so for % BW (*p* = 0.0531).

Sequencing of RNA libraries produced over 195 M reads. The number of reads per library ranged from 10.8 M to 14.6 M (average 12.2 M, [Table 1](#toxins-10-00042-t001){ref-type="table"}). After trimming and filtering, median Q scores were consistently high and ranged from 36.4 to 37.4 among the forward and reverse reads. The number of reads per treatment group was balanced and ranged from 11.5 to 12.7 M, with an average of 12.21 ± 0.5 M. Approximately 91% of the quality-trimmed reads mapped to the annotated turkey gene set (NCBI Annotation 101, [Table 1](#toxins-10-00042-t001){ref-type="table"}). This percentage was consistent across treatment groups and the percentage of aligned read pairs exceeded 89.7% (average = 90.8%); the majority of reads (average = 85.3%) mapped concordantly ([Table 1](#toxins-10-00042-t001){ref-type="table"}). Based on mapping, the estimated mean library insert was 191.7 bp.

Principal component analysis (PCA) of normalized read counts visualized variation among the treatment groups ([Figure 1](#toxins-10-00042-f001){ref-type="fig"}). Groups clustered distinctly according to treatment (AFB~1~ versus control) within the first two principal components, accounting for approximately 95% of the observed variation. Hierarchical clustering of groups by Euclidean distance reiterated the relationships shown by PCA ([Figure S1](#app1-toxins-10-00042){ref-type="app"}). After segregating by AFB~1~ treatment, groups secondarily cluster by type (domesticated versus wild), with the exception of samples N3L (domesticated) and EW1L (wild) that clustered with the opposite bird type. Significant differences in overall gene counts among groups are shown in the heat map of co-expressed genes.

2.1. Gene Expression {#sec2dot1-toxins-10-00042}
--------------------

Evidence of expression (mean mapped reads ≥ 1.0 in at least one treatment group) was detected for 19,764 genes (tRNAs excluded), with an average of 17,137.5 genes being detected per group (81.56% of the turkey gene set) ([Table S1](#app1-toxins-10-00042){ref-type="app"}). Mean read depth was 394.8 reads per gene. When limited to an average number of mapped reads ≥ 3.0, the number of expressed genes ranged from 14,399 to 17,230 among treatment groups (average 15,979.25, [Table 1](#toxins-10-00042-t001){ref-type="table"}). Distribution of unique and shared expressed genes is illustrated in [Figure S2](#app1-toxins-10-00042){ref-type="app"}. A total of 14,373 genes (81.2%) was co-expressed among all groups, and the number of co-expressed genes within the EW and DT lines was 14,908 and 14,669, respectively. Each treatment group had distinct sets of uniquely expressed genes, but that number was considerably greater in the AFB~1~-treatment groups (2169, 12.3%) when compared to controls (300, 1.6%, [Table 1](#toxins-10-00042-t001){ref-type="table"} and [Table S1](#app1-toxins-10-00042){ref-type="app"}).

2.2. Differential Transcriptomic Expression: AFB~1~ Effects {#sec2dot2-toxins-10-00042}
-----------------------------------------------------------

[Table S2](#app1-toxins-10-00042){ref-type="app"} provides the full list of genes showing significant differential expression (DE). DE was observed for 9620 genes (FDR *p*-value \< 0.05, log~2~FC = −9.670 to 9.358) in wild turkeys exposed to AFB~1~ when compared to control birds with 4176 genes having \|log~2~FC\| \> 2.0 ([Table 2](#toxins-10-00042-t002){ref-type="table"}). Similarly, 11,325 DE genes were observed for the AFB~1~-treated DT turkeys (FDR *p*-value \< 0.05, log~2~FC = −14.133 to 12.676) with 4621 genes having \|log~2~FC\| \> 2.0. The majority of DE genes (3380) were shared in both bird types, with 796 being unique to wild and 1241 unique to the domesticated birds ([Figure 2](#toxins-10-00042-f002){ref-type="fig"}). The majority of DE genes was up regulated by AFB~1~ treatment in both the wild (2717, 65%) and domesticated birds (2914, 70%). Of the 50 genes showing the greatest fold change with treatment, seven (*ANGPTL3* \[angiopoietin-like 3\], *GC* \[group-specific component (vitamin D binding protein)\], *LOC104911607* \[uncharacterized ncRNA\], *LOC100541166* \[alpha-1-acid glycoprotein 2-like\], *LOC100542070* \[*SERPINA1*-like, alpha-1-antitrypsin-like\], *NME4* \[NME/NM23 nucleoside diphosphate kinase 4\], and *TAT* \[tyrosine aminotransferase\]) were shared between the bird types ([Table S3](#app1-toxins-10-00042){ref-type="app"}). In mammals, *ANGPTL3* is in part involved in regulation of lipid and glucose metabolism by inhibiting the lipolysis of triglyceride-rich lipoproteins \[[@B29-toxins-10-00042],[@B30-toxins-10-00042]\]. This transcript was highly down regulated in the AFB~1~-treated turkeys (log~2~FC = −7.94 and −14.13 in EW and DT, respectively). Similarly down regulated was *GC* an important protein in vitamin D transport and storage, actin-scavenging, and enhancement of complement component 5a activity for neutrophils in inflammation and during macrophage activation \[[@B31-toxins-10-00042]\]. Comparison analysis in IPA found the most significant canonical pathways to include "Axonal Guidance Signaling" and "Hepatic Fibrosis/Stellate Cell activation". Hepatic stellate cells are closely linked to the progression of hepatic fibrosis \[[@B32-toxins-10-00042]\].

### 2.2.1. Shared DE Genes {#sec2dot2dot1-toxins-10-00042}

Changes in expression of the 3380 shared significant DE genes were highly correlated (r^2^ = 0.909, F = 0.010, [Figure S1](#app1-toxins-10-00042){ref-type="app"}) and essentially linear, except for genes with the greatest down regulation where log~2~FC in the domestic birds tended to be of greater magnitude than observed for the wild birds. This is consistent with a common physiological response to AFB~1~ exposure. Of the 3380 shared DE genes, 1609 IDs mapped to the *G. gallus* gene REFLIST and statistical overrepresentation tests (PANTHER) of these shared DE genes found the greatest enrichment in the Biological Process category for "amino acid processes" and "negative regulators of hemostasis and wound healing" ([Table S4](#app1-toxins-10-00042){ref-type="app"}). Comparison analysis in IPA found the most significant toxicology functions consistent with cellular damage. Categories with the greatest number of included genes included "liver hyperplasia/hyperproliferation" (*p* = 5.10 × 10^−41^), "cardiac hypertrophy" (*p* = 2.91 × 10^−12^), "renal necrosis/cell death" (*p* = 7.78 × 10^−12^), and "liver steatosis" (*p* = 1.75 × 10^−11^). Highest activation (Z) scores were obtained for "Integrin Signaling", "Rho Family GTPase signaling", and "NFAT regulation of immune response" pathways.

Only two loci among the 3380 shared significant DE genes showed opposite directional expression changes between wild and domesticated birds. *CD96*, a T cell-specific receptor, was significantly up regulated in response to AFB~1~ in the EW birds (log~2~FC = 3.83) but down regulated in DT (log~2~FC = −2.15). CD96 may play a role in the adhesive interactions of activated T and NK cells when actively engaging diseased cells within areas of inflammation \[[@B33-toxins-10-00042]\]. A second locus (*LOC104911020*, serum amyloid A protein-like) was significantly down regulated in response to AFB~1~ in EW birds (log~2~FC = −3.99), but up regulated in DT (log~2~FC = 2.22). Serum amyloid A (SAA) proteins are a family of apolipoproteins produced primarily by the liver and are associated with high-density lipoprotein in plasma \[[@B34-toxins-10-00042]\].

### 2.2.2. Unique Responses {#sec2dot2dot2-toxins-10-00042}

Although the greatest number of DEGs was shared between the domesticated and wild turkey comparisons, 796 DEGs were uniquely affected in the wild birds exposed to AFB~1~ in comparison to their controls ([Figure 2](#toxins-10-00042-f002){ref-type="fig"}). Up-regulated genes with the greatest fold change in the EW birds ([Table S3](#app1-toxins-10-00042){ref-type="app"}) included several transcription factors (*DMRT2*, *FOXF2*, *HOXD10*, *HOXA9*, *HOXD8*) and transporters (*LOC100548321* \[pendrin\], *SLC13A1*, *SLC6A18*). DEGs with the greatest negative fold change (down regulated) include the cytochrome P450s (*LOC100548279* \[*CYP2K4*-like\], *LOC100546803* \[*CYP8B1*\], and *LOC100539035* \[*CYP7A1*\]), metabolic inhibitors (*LOC100542224* \[alpha-1-antitrypsin-like\], *INHBC* \[inhibin, beta C\], *LOC104912821* \[ovostatin homolog\], *LOC104915655* \[alpha-2-macroglobulin-like\]), and several ncRNAs. Of the 796 unique DEGs in the EW comparison, 336 had mapped IDs in *G. gallus* REFLIST and overrepresentation tests in PANTHER found greatest enrichment in the Biological Process category were genes in the GO classifications of "negative regulation of neurogenesis" (GO:0050768) and "negative regulation of cell development" (GO:0010721) with 5.58- and 5.13-fold enrichment, respectively ([Table 3](#toxins-10-00042-t003){ref-type="table"}). Effected Cellular Component groups included "elements of the sarcolemma" (GO:0042383) and "proteinaceous extracellular matrix" (GO:0005578) enriched by 7.65- and 3.92-fold, respectively.

A greater number of DEGs (1241) were uniquely affected in the domesticated birds exposed to AFB~1~, in comparison to their controls. Of the 50 DEGs with the greatest fold change in the domesticated birds, only two were up regulated; *SMIM24* (small integral membrane protein 24) and *LOC100546964* (cis-aconitate decarboxylase-like) ([Table S3](#app1-toxins-10-00042){ref-type="app"}). The function of SMIM24 is currently unknown. In humans, cis-aconitate decarboxylase (*ACOD1* = *IRG1*) is highly expressed in mammalian macrophages during inflammation where it catalyzes itaconic acid production \[[@B35-toxins-10-00042]\]. Among the most down-regulated loci in DT were *ANGPTL3* (angiopoietin-like 3) which in humans, is expressed predominantly in the liver and functions in angiogenesis, and Fibrinogen (*FGA*, *FGB*, and *FGG*) and other coagulation components like coagulation factor IX (*F9*). This set of down-regulated DEGs also included *LOC100547030* (a cytochrome P450 2W1-like gene). In humans, CYP2W1 is able to metabolically activate several pro-carcinogens, including AFB~1~, into cytotoxic products \[[@B36-toxins-10-00042]\]. Due to its selective expression, *CYP2W1* is suggested as a potential prognostic biomarker in hepatocellular and other carcinomas \[[@B37-toxins-10-00042]\].

GO analysis of the DEGs unique to the domestic turkey liver indicate a number of distinctive responses to AFB~1~. Of the 1241 DEGs, 636 mapped to IDs in *G. gallus* REFLIST and overrepresentation tests in PANTHER found the greatest enrichment for biological process categories "organelle fission" (GO:0048285), "oxidation-reduction process" (GO:0055114), and "regulation of immune system process" (GO:0002682) ([Table 4](#toxins-10-00042-t004){ref-type="table"}). Cellular component categories were enriched for mitochondrial and membrane components.

2.3. Differential Transcriptomic Expression: Eastern Wild vs. Domesticated Turkey {#sec2dot3-toxins-10-00042}
---------------------------------------------------------------------------------

### 2.3.1. Control {#sec2dot3dot1-toxins-10-00042}

Comparison of the transcriptomes of control EW and DT birds found 774 DEGs (FDR *p*-value \< 0.05, log~2~FC = −8.826 to 8.213), with 184 having log~2~FC \> 2.0 ([Figure 3](#toxins-10-00042-f003){ref-type="fig"}, [Table S5](#app1-toxins-10-00042){ref-type="app"}). Of the 184 genes, seven were shared in common in the EW vs. DT AFB~1~ comparisons ([Figure 3](#toxins-10-00042-f003){ref-type="fig"}). The shared loci included 5 genes up regulated in EW birds (*ANGPTL3*, *CAMK4*, *LOC100538933* \[probable ATP-dependent RNA helicase *DDX60*\], *LOC100545362* \[ncRNA\], *LOC104912934* \[ncRNA\]), and two that were down regulated (*LOC104910139* \[ncRNA\], *LOC104915640* \[*KIAA1755* homolog\]) when compared to DT. These shared genes are primarily metabolic and transcriptional regulators. In mammals, ANGPTL3 \[angiopoietin-like 3\] is a hepatokine involved in regulation of lipid and glucose metabolism and in the regulation of angiogenesis \[[@B37-toxins-10-00042]\], CAMK4 \[calcium/calmodulin-dependent protein kinase IV\] is implicated in transcriptional regulation in immune and inflammatory responses \[[@B39-toxins-10-00042]\], and DDX60 positively regulates DDX58/RIG-I- and IFIH1/MDA5-dependent type I interferon and interferon inducible gene expression \[[@B40-toxins-10-00042]\].

Of the 177 DEGs unique to the control group birds the majority (69%) were up regulated in the wild birds as compared to the domesticated birds. GO analysis found only a single biological process category ("single-organism process" GO:0044699) enriched among these genes (fold enrichment = 1.66, *p*-value = 4.15 × 10^−2^). Interestingly, the up-regulated DEGs observed in the control-diet comparison also included glutathione S-transferase A3 (*GSTA3*). This gene was expressed at a 5.3-fold higher level (log~2~FC = 2.313) in the EW birds when compared to the DT birds ([Figure 4](#toxins-10-00042-f004){ref-type="fig"}A), suggesting a higher constitutive expression in the former.

The genes showing the greatest positive fold change was the Interferon-inducible iron-sulfur cluster-binding antiviral protein *RSAD2*, radical S-adenosyl methionine domain containing 2, with log~2~FC = 8.2 and the interferon alpha-inducible protein 27-like 2B (*IFI27L2B*, *LOC100550948*). In mammals, RSAD2 can inhibit a wide range of DNA and RNA viruses, and has also been shown to play a role in CD4+ T-cells activation and differentiation \[[@B41-toxins-10-00042]\], whereas IFI27L2B mediates virus-induced apoptosis \[[@B42-toxins-10-00042]\]. These suggest heightened immune system activity in the wild birds.

Two genes involved in cell cycle control and chromosomal replication were also expressed at a significantly higher level in the wild bird controls. *CD1*, chromatin licensing and DNA replication factor 1 and *MCM3*, minichromosome maintenance complex component 3 had log~2~FC = 2.74 and 2.4, respectively ([Table S5](#app1-toxins-10-00042){ref-type="app"}). Interestingly several other genes involved "cell cycle control" and "chromosomal replication" were also significantly up regulated in the wild birds, although with log~2~FC \< 2.0 ([Table S2](#app1-toxins-10-00042){ref-type="app"}). These included *CDC45* (cell division cycle 45), *DNA2* (DNA replication helicase/nuclease 2), the minichromosome maintenance complex components *MCM2*, *MCM4*, *MCM5*, *MCM6*, and *MCM8*, and *POLE* (DNA polymerase epsilon, catalytic subunit). These together with *CD1* and *MCM2* were components of the most significant Canonical Pathway identified by IPA (*p* = 1.1 × 10^−8^, ratio 0.25). Genes showing the greatest negative fold change were *GYG2* (glycogenin 2), *IQCD* (IQ Motif Containing Protein D), and *LOC100540418* (BPI fold-containing family C protein-like) ([Table S5](#app1-toxins-10-00042){ref-type="app"}). GYG2 is involved in the initiation reactions of glycogen biosynthesis \[[@B43-toxins-10-00042]\], and IQCD has been shown to interact with the RXR nuclear hormone receptor, and is thought to function as a transcriptional coactivator \[[@B44-toxins-10-00042]\].

### 2.3.2. AFB~1~ Treatment {#sec2dot3dot2-toxins-10-00042}

Comparison of the transcriptomes of EW and DT birds fed the AFB~1~ diet revealed 903 DEGs (FDR *p*-value \< 0.05, log~2~FC = −7.987 to 9.262), of which, 143 had log~2~FC \> 2.0 ([Figure 3](#toxins-10-00042-f003){ref-type="fig"}, [Table S5](#app1-toxins-10-00042){ref-type="app"}). Of these 143 DEGs, 136 were unique to the AFB~1~-treated birds. The majority (76%) of the DEGs were up regulated in EW relative to DT in a similar fashion to that seen for the control-group comparison. Unlike the control-fed groups, GO analysis found the DE genes from the AFB~1~ between-line comparison highly enriched in several biological process categories ([Table 5](#toxins-10-00042-t005){ref-type="table"}) including processes related to coagulation, inflammatory response and apoptosis. For example, up regulated in EW relative to DT were three components of the blood clotting factor fibrinogen (*FGA*, *FGB*, and *FGG*) and several other coagulation-related genes (vitamin K-dependent coagulation factor IX (*F9*), serpin peptidase inhibitor, member 10 (*SERPINA10*), histidine-rich glycoprotein (*HRG*), serpin peptidase inhibitor, clade C (antithrombin), member 1 (*SERPINC1*)). Although down-regulated genes did not show significant enrichment for a particular bioprocess, EW birds may produce less of the pro-inflammatory cytokine IL-17A (*LOC100546746*).

Expression of many enzymes responsible for xenobiotic metabolism, with an emphasis on those with specificity towards AFB~1~, was significantly altered by the AFB~1~ treatment ([Table 6](#toxins-10-00042-t006){ref-type="table"}). With a few exceptions, AFB~1~ largely caused down regulation of these genes in both types of turkeys when compared to controls; within the control groups, the number of DEGs was considerably smaller and the magnitude of expression changes was also smaller, but directionally similar. Hepatic expression of CYP and GST genes was typically greater in EW vs. DT. Five cytochrome P450 loci; *CYP1A5* (cytochrome P450, family 1, subfamily A, polypeptide 5, log~2~FC = 2.404), *LOC100547030* (cytochrome P450 2W1-like, log~2~FC = 5.87), *LOC100542486* (cytochrome P450 1A4, log~2~FC = 3.150), *LOC100548433* (cytochrome P450 2K1-like, log~2~FC = 3.025), and *LOC104915479* (cytochrome P450 2H1-like, log~2~FC = 2.135) were among the unique DEGs in the EW vs. DT comparison.

The turkey possesses six α-GST cluster genes, all of which possess detectable enzymatic activities toward prototype substrates in a recombinant expression system \[[@B19-toxins-10-00042]\], unlike hepatic forms. Expression of the GSTAs was significantly altered by AFB~1~ treatment. With the exception of *GSTA3*, *GSTA1.1*, *1.3*, *2* and *4* were down regulated, while *GSTA3* increased with dietary AFB~1~ in DT but not EW (log~2~FC = 1.4667, [Table 6](#toxins-10-00042-t006){ref-type="table"}). It is noteworthy that *GSTA3* expression was significantly higher in EW birds when compared to DT birds for both control (log~2~FC = 2.3130) and AFB~1~ (log~2~FC = 0.9211) group comparisons ([Table 6](#toxins-10-00042-t006){ref-type="table"}, [Figure 4](#toxins-10-00042-f004){ref-type="fig"}A).

Expression differences in *GSTA3* observed in RNA-seq read counts were confirmed by qRT-PCR. *GSTA3* expression varied widely among treatment groups with experiment-wise threshold values (ΔCt) ranging from 17.27 to 26.06. Expression of *GSTA3* transcripts was significantly higher in AFB~1~-treated birds than controls for both genetic groups (EW, *p* = 0.0061 and DT, *p* = 0.0036). Relative *GSTA3* expression was also similarly variable in the other commercial (BB) and wild-type birds (RGW) ([Figure 4](#toxins-10-00042-f004){ref-type="fig"}B) where *GSTA3* expression was higher in AFB~1~-treated birds. This difference, however, was only significant in the BB comparison (*p* = 0.0015). Relative expression in BB birds was slightly higher than observed in the DT (Nicholas strain) birds and also higher in RGW birds (Rio Grande wild) when compared to EW. This result demonstrates that the differences observed in *GSTA3* expression between the EW and DT birds is not unique to these genetic lines but is a broader, wild versus domesticated-bird phenomenon.

3. Discussion {#sec3-toxins-10-00042}
=============

When compared to their domestic relatives, wild turkeys are relatively resistant to aflatoxicosis. This difference is largely due to functional hepatic GSTA-mediated detoxification activity of the bioactive electrophilic AFBO intermediate that is completely lacking in domesticated birds \[[@B20-toxins-10-00042]\]. The present data indicates other pathways may also account for difference in AFB~1~ susceptibility, such as cellular regulation, modulation of apoptosis, inflammatory responses, and other pathways relevant to AFB~1~ pathogenesis. The liver is the principal organ of AFB~1~ bioactivation and detoxification \[[@B6-toxins-10-00042],[@B21-toxins-10-00042],[@B22-toxins-10-00042],[@B24-toxins-10-00042],[@B45-toxins-10-00042]\]. In turkeys, AFB~1~ causes reduced feed intake, weight gain, and immunological function in a dose-dependent fashion \[[@B46-toxins-10-00042],[@B47-toxins-10-00042]\]. Dietary exposure in poultry causes lipid accumulation, resulting in hepatomegaly and increases in liver:body weight ratios \[[@B48-toxins-10-00042],[@B49-toxins-10-00042],[@B50-toxins-10-00042]\]. During the 14 day exposure, decreased relative liver mass initially occurred in both EW and DT consistent with that observed in chickens \[[@B49-toxins-10-00042]\] and wild turkeys \[[@B9-toxins-10-00042]\].

Numerous significant DEGs occurring in the livers of AFB~1~-treated birds have potential roles in lipid metabolism or accumulation. AFB~1~ is known to alter lipid metabolism and increase lipid content resulting in pale or yellowed pigmentation \[[@B46-toxins-10-00042]\]. Dietary AFB~1~ primarily down regulated several hepatic apolipoprotein genes (cofactors in lipid binding and transport) in the turkey, and dis-regulation of genes, such as *ANGTPL3*, would have direct effects on lipids. Significant up regulation of *ANGTPL3* was observed for both EW and DT birds treated with AFB~1~. This would likely stimulate synthesis of plasma triglycerides (TG) via the inhibition of lipoprotein lipase (LPL) activity. In both AFB~1~-treated groups, *LPL* was significantly down regulated (log~2~FC = −2.905 and −6.032 in EW and DT birds, respectively). LPL functions in the hydrolysis of triglycerides in lipoproteins and is essential to lipid metabolism and storage. Significant down regulation of *LPL* was also observed in our previous analyses of AFB~1~-treated domesticated Orlopp turkeys \[[@B26-toxins-10-00042]\] and decreased expression of LPL occurs in AFB~1~-treated chickens \[[@B50-toxins-10-00042]\].

As expected, the significant hepatic DEGs included the Phase I and II detoxifying enzymes that we have shown are relevant to AFB~1~ exposure in turkeys ([Table 6](#toxins-10-00042-t006){ref-type="table"}). Previous studies have demonstrated efficient epoxidation by hepatic turkey cytochromes CYP1A5 and CYP3A37 \[[@B16-toxins-10-00042]\]. At environmentally-relevant hepatic concentrations (\<50 uM) CYP1A5 bioactivates the majority (\~98%) of AFB~1~ \[[@B17-toxins-10-00042],[@B21-toxins-10-00042]\], whereas CYP3A37 predominates at much higher substrate concentrations unlikely to be achieved in the livers of exposed animals \[[@B16-toxins-10-00042]\]. Based on RNA-seq, it is clear that dietary AFB~1~ significantly down regulated *CYP1A5* in both EW and DT birds, but more significantly so in DT. This result is at odds with our earlier findings in another strain of DT (Orlopp) where almost no expression change was observed for *CYP1A5* and *CYP3A37*, and where none of the transcripts associated with CYP genes had significant DE as a result of AFB~1~ treatment \[[@B26-toxins-10-00042]\]. Significant down regulation of *CYP1A5* in response to AFB~1~ was also observed in ducks, another avian species with high AFB~1~ susceptibility \[[@B51-toxins-10-00042]\]. Several other P450 genes in addition to *1A5* and *3A37* had significant DE in the present study ([Table 6](#toxins-10-00042-t006){ref-type="table"}), including both *CYP2W1* and *CYP2K1*. Interestingly, these genes have been shown in other species to activate AFB~1~ into cytotoxic products \[[@B52-toxins-10-00042],[@B53-toxins-10-00042]\]. We have found *CYP2W1*-like transcripts to have significant DE in DT embryos challenged with AFB~1~ \[[@B28-toxins-10-00042]\]. Down regulation of *CYP1A5* in both EW and DT birds could affect their overall ability to bioactivate AFB~1~. However, as this expression change was seen in both bird types, it does not account for the differences seen in AFB~1~ susceptibility \[[@B16-toxins-10-00042]\].

Expression of GSTs with affinity toward AFBO is a known predictor of relative AFB~1~ resistance \[[@B20-toxins-10-00042]\]. Constitutive expression of *GSTA3*, the ortholog to the putative AFB~1~-protective GSTA3 isoform in mice \[[@B18-toxins-10-00042]\] was significantly higher in EW than in DT birds. Dietary AFB~1~ caused significant down-regulation of hepatic α-class GSTs, with the exception of *GSTA3*, where increased expression of this isoform was observed in the AFB~1~-treated DT group. This pattern was also observed in the qRT experiments of other wild (RGW) and domesticated (BB) turkeys. A similar pattern of *GSTA3* expression in response to AFB~1~ was also observed in turkey embryos early after exposure, where small increases were observed in DT \[[@B28-toxins-10-00042]\] and in ducks \[[@B51-toxins-10-00042]\].

Expression of *GSTA3* mRNA in turkeys is not correlated with AFB~1~ sensitivity in that domesticated birds lack hepatic GST-mediated AFBO conjugating activity \[[@B19-toxins-10-00042]\], despite expression of *GSTA3*. Hepatic cytosols isolated from wild turkeys possess functional AFBO-trapping GSTs \[[@B20-toxins-10-00042]\]. While hepatic GSTs in DT lack detoxification activity, with or without AFB~1~ treatment, increased *GSTA3* expression in DT in response to AFB~1~ may reflect a greater inflammatory response or perhaps an indicator of hepatocyte injury. Although GSTs are toxicologically important for their role in "trapping" electrophilic intermediates by conjugating with the nucleophilic GSH, they may also play a role in cell signaling through binding of non-substrate ligands to mediate cell proliferation and cell death \[[@B54-toxins-10-00042]\]. Up regulation of *GSTA*s may also reflect antioxidant functions as AFB~1~, exposure in poultry can lead to oxidative stress and lipid peroxidation \[[@B55-toxins-10-00042],[@B56-toxins-10-00042]\]. When combined, these results support the hypothesis that the greater ability of wild turkeys to detoxify AFB~1~ is related to higher constitutive expression of *GSTA3*, coupled with an inherited (genetic) difference in functional expression in domesticated birds. Expression in these *CYP* and *GSTAs* suggests that the physiological response to AFB~1~ is mediated through genes not experimentally linked in the turkey to AFB~1~ metabolism.

Up regulation of transcription factors and metabolic inhibitors characterized the shared response to AFB~1~. Taken together, these are genes that comprise the molecular mechanisms underlying aflatoxicosis. Recurrent themes amongst the many DEGs of AFB~1~-treated birds are linked by functional analysis to inflammation, apoptosis, the cell cycle (cancer), or lipid regulation, suggesting common underlying regulation. For example, recent studies of AFB~1~-induced hepatocellular carcinoma have examined regulatory ncRNAs (miRNA and lncRNA) \[[@B57-toxins-10-00042],[@B58-toxins-10-00042]\]. Studies in the rat, another AFB~1~-susceptible species, have found coincident DE of transcripts that are related to these same functions and specific lncRNAs in hepatocellular carcinomas \[[@B59-toxins-10-00042],[@B60-toxins-10-00042]\]. Our study of miRNA expression in the same turkey liver tissues used in the present study is currently underway (Coulombe, unpublished).

Transcriptome analysis not only includes genes responding to the presence of AFB~1~, but also reveals genes dis-regulated as a response to toxic insult. Significant up regulation was seen for several vasoactive peptides, including, neuropeptide Y (*NPY*), somatostatin (*SST*), substance P (tachykinin, *TAC1*), and vasoactive intestinal peptide (*VIP*), suggesting altered sinusoidal blood flow with AFB~1~ treatment. Also, affected were extracellular matrix proteins including glycoproteins (e.g., HAPLN1 and HAPLN3), protein receptors (*KERA*, *LAMB3*, *LUM*, *LRRN2*, and *LRRN3*), proteinase inhibitors (*TIMP4*), signaling molecules (*SFRP1*, *Wnt6* and *7a*), and structural proteins (*COL10A1*, *FRAS1*). Expression of the majority of the ADAM metallopeptidases was altered in AFB~1~ treatment ([Table S2](#app1-toxins-10-00042){ref-type="app"}). Some of these proteases are thought to be involved in regulating matrix degradation \[[@B61-toxins-10-00042]\]. Unique response in the EW birds was seen in genes that negatively regulate cellular processes, components of the extracellular matrix and accumulation of coagulation factors. DT birds showed greater up regulation of genes responding to inflammation, which was likely due to the reduced ability to detoxify AFBO. Dis-regulation of extracellular matrix proteins is a resulting effect of chronic liver injury \[[@B32-toxins-10-00042]\]. Aflatoxin inhibits cell-mediated immunity in domestic poults \[[@B47-toxins-10-00042],[@B62-toxins-10-00042]\] with the suppression of lymophoblastogenesis \[[@B9-toxins-10-00042]\], T-helper, or cytotoxic T-cell activity \[[@B63-toxins-10-00042]\].

Multiple genes involved in pathways of coagulation (*FGA*, *FGB*, *FGG*, *F9*, *HRG*, *SERPINA10*, and *SERPINC1*) were expressed at higher levels in EW as compared to DT, where they were among the genes with the highest negative fold change. Lower expression of coagulation factors was also seen in livers of domesticated turkey embryos after just 5 days of exposure to AFB~1~ \[[@B28-toxins-10-00042]\]. AFB~1~ has been shown to increase blood clotting times in poultry \[[@B64-toxins-10-00042],[@B65-toxins-10-00042]\] and activities of coagulation factors, such as F9, were reduced by dietary AFB~1~ in chickens \[[@B50-toxins-10-00042],[@B65-toxins-10-00042]\]. Effects on hemostasis are more dramatic in turkeys than chickens \[[@B66-toxins-10-00042]\]. In comparison, only small non-significant increases in prothrombin times were seen in wild turkeys exposed to AFB~1~ \[[@B9-toxins-10-00042]\], which is consistent with the gene expression patterns observed in the liver transcriptomes.

In a previous comparison of EW and DT after *in ovo* exposure \[[@B28-toxins-10-00042]\], we used RNA-seq to examine gene expression responses to AFB~1~ in the embryonic hepatic transcriptomes and identified gene expression effects dependent on exposure time and turkey type. Most notable in turkey embryos was the more rapid response of the DT, which was likely due to their lack of GST activity towards the AFBO-epoxide. The present study was designed to contrast gene expression responses in the hepatic transcriptome of growing domesticated and wild turkeys during AFB~1~ exposure. In conclusion, our findings emphasize the differential response of these genetically distinct birds, demonstrating significant differences in expression of Phase I and Phase II genes and in genes important in cellular regulation, modulation of apoptosis, and inflammatory responses. The molecular basis for the differences in AFB~1~ detoxification observed between EW and DT birds, and the mechanism of GSTA silencing in DT remain under investigation.

4. Materials and Methods {#sec4-toxins-10-00042}
========================

This study used two turkey subspecies previously demonstrated to vary in AFB~1~-detoxifying GST activity. Eggs from domesticated (DT = Nicholas) and a wild subspecies (Eastern wild = EW, *Meleagris gallopavo silvestris*) were obtained from Privett Hatchery (Portales, NM, USA) and hatched at Utah State University. Birds were sexed by PCR \[[@B67-toxins-10-00042]\]. Male turkey poults were maintained on an *ad libitum* standard grow-up soy-based diet and acclimated to the facility for two weeks. At the end of this period, males from each line (*n* = 8 for EW and *n* = 10 for DT) were equally assigned to one of two treatment groups and subjected to a short-term AFB~1~-treatment protocol \[[@B21-toxins-10-00042],[@B68-toxins-10-00042]\]. For the AFB~1~ treatment, the diet of challenge birds was amended beginning on day 15 with 320 ppb AFB~1~ (Sigma-Aldrich, Inc., St. Louis, MO, USA) that continued for 14 days. Control birds continued on the standard diet with AFB~1~ levels below detection limits (\<10 ppb), based on testing of 50 g of feed extracted and cleaned using Mycosep 112 AflaZON cleanup columns (Romer Labs., Union, MO, USA), and examined by HPLC. Birds were weighed three times per week and feed and water availability checked daily. At the conclusion of the 14 day challenge period, birds were sacrificed by CO~2~ asphyxiation and blood collected by cardiac puncture for DNA and serological analysis. Livers were removed, examined, weighed, sampled, and fixed in neutral buffered formalin for histological examination. Portions of the liver tissues infused with RNAlater (ThermoFisher Scientific, Waltham, MA, USA) for RNA-Seq analysis. All of the procedures were under the authority and institutional approval of Utah State University's Animal Use and Care Committee. Ethical approval code: 2670, Date of approval: 26 September 2016.

4.1. RNA Isolation and Sequencing {#sec4dot1-toxins-10-00042}
---------------------------------

Total RNA was isolated from each sample by TRIzol extraction (Ambion, Inc., Foster City, CA), DNase-treated (Turbo DNA-freeTM Kit, Ambion, Inc.), and stored at −80 °C. Initial RNA concentration and quality was assessed by spectrophotometry (Nanodrop 8000). RNA samples were submitted for library preparation and sequencing at the University of Minnesota Genomics Center (UMGC). Replicate samples were sequenced from each treatment group (*n* = 4). Each sample was quantified by RiboGreen assay (Invitrogen Corp., Carlsbad, CA, USA) and RNA integrity confirmed on a 2100 Bioanalyzer (Aligent Technologies, Santa Clara, CA, USA). Each sample had clear 18S and 28S peak separation on the electropherograms and an average RNA Integrity Number (RIN) of 6.3. Indexed libraries (*n* = 16) were constructed with 1 μg of total RNA/sample with the TruSeq RNA Sample Preparation Kit version 2 (Illumina, Inc., San Diego, CA, USA) and size selected for approximately 200 bp inserts. Libraries were multiplexed, pooled, and sequenced over two lanes on the HiSeq 2000 using v3 chemistry (Illumina, Inc.) to produce 101-bp paired-end reads. Data are deposited in the NCBI Gene Expression Omnibus (GEO) repository as part of SRA BioProject 346253.

4.2. RNA-seq Data Analyses {#sec4dot2-toxins-10-00042}
--------------------------

Sequence reads were groomed (Trimmomatic, \[[@B69-toxins-10-00042]\]) and quality checked (FastQC, \[[@B70-toxins-10-00042]\]) prior to read mapping (Bowtie v2.2.4.0) on the turkey genome (UMD 5.0, NCBI Annotation 101). Read counts were normalized in CLC Genomics Workbench (CLCGWB v. 8.0.2, CLC Bio, Aarhus, Denmark) by dividing the total read counts by the group sample sum with the results being expressed as reads per 12.2 M. Hierarchical clustering of samples was performed (based on Euclidean sample distances with single linkage) in CLCGWB. Principal component analysis (PCA), Volcano plots, and Venn diagrams were used to visualize expression data and the results of significance testing. Empirical analysis of differential gene expression and ANOVA were performed in CLCGWB on EdgeR-normalized read counts. Pair-wise comparisons between treatment groups were made in CLCGWB following the standard workflow Wald test with multi-comparison *p*-values \< 0.05 being considered as significant (Bonferroni and FDR corrected). In each pair-wise comparison, significant DE genes were used to investigate affected gene pathways using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA, USA). Gene enrichment tests were performed using the PANTHER Overrepresentation Test (GO Consortium release 20150430, \[[@B38-toxins-10-00042]\]).

4.3. Quantitative Real-Time PCR {#sec4dot3-toxins-10-00042}
-------------------------------

To more broadly examine the expression profile response of *GSTA3* to dietary AFB~1~, quantitative real-time PCR (qRT-PCR) was performed on both domesticated and wild turkey liver samples. Samples included AFB~1~-treated and control animals (six per group) from the domesticated Nicholas turkey (DT) and Eastern Wild (EW) experiment, plus AFB~1~-treated and control animals (six per group) of a parallel experiment that included domesticated Broad Breasted White (BB), and birds of the Rio Grande subspecies (RGW, *M. g. intermedia*) of wild turkey. Four of the six samples for the DT and EW groups were in common with the RNA-seq study.

Briefly, cDNA was synthesized from DNase-treated liver mRNA (TRIzol extracted) using Invitrogen Super Script IV First-strand synthesis kit (Invitrogen, Carlsbad, CA, USA). Expression analysis of gene-specific amplicons was performed with the iTaq Universal SYBR Green Supermix (BioRad, Hercules, CA, SA) with the CFX96 touch real time detection system (BioRad, Hercules, CA, USA). Primers were designed within Primer3 software (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>) from accessioned genomic DNA sequence (NM_001303157.1) to span an exon/exon junction and at least one intron in the amplicon. RefFinder software was utilized to determine the most stable reference gene. Several normalizing genes were tested for uniformity between treatments and lines and RNA polymerase II subunit D (*POLR2D*, XM_003208947) was found to have the highest stability value (0.848). Target gene reactions were conducted in triplicate, and *POLR2D*, no template and gDNA controls were run in duplicate. All of the reactions included a disassociation curve to confirm a single product and to preclude the possibility of dimers amplifying. Expression in each RNA sample was normalized first to the control gene *POLR2D*. Results were interpreted using the Double Delta Ct Analysis (ΔΔCt, \[[@B71-toxins-10-00042]\]) and a comparative Ct approach. Expression analysis was performed within the Biorad CFX Maestro software package following the standard ΔΔCt workflow.

This project was supported by Agriculture and Food Research Initiative Competitive Grant No. 2013-67015-21241 from the USDA National Institute of Food and Agriculture. This research was also supported in part by the Minnesota and Utah Agricultural Experiment Stations, and approved as Utah Agricultural Experiment Station journal paper number 9060.

The following are available online at [www.mdpi.com/2072-6651/10/1/42/s1](www.mdpi.com/2072-6651/10/1/42/s1). Figure S1: Hierarchical clustering of samples based on Euclidean distance reiterated relationships shown by PCA. Figure S2: Distribution of genes expressed in turkey liver by treatment group. Figure S3: Differential fold change in DEGs shared by Eastern wild (EW) and domesticated (DT) birds exposed to AFB~1~ in comparison to controls. Table S1. Mean quality-trimmed RNA-seq read counts for genes with mapped reads in the livers of wild and domesticated turkeys. Table S2. Summary of pairwise differential gene expression analysis of liver transcriptomes. Table S3. Fifty genes showing the greatest differential expression in each pairwise comparison of treatment groups. Table S4. Summary of PANTHER Overrepresentation test of the 3380 differentially expressed genes shared in the AFB~1~-treated birds as compared to controls. Table S5. Significant differentially expressed genes (FDR *p*-values \< 0.05 and \|log~2~FC\| \> 2.0) identified in each pairwise comparison of genetic groups (Eastern wild and domesticated turkey).
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![Principal component analysis (PCA) of normalized RNA-seq read counts. For each treatment group, sample to sample distances (within- and between-treatments) are illustrated on the first two principal components comprising approximately 95% of the variation.](toxins-10-00042-g001){#toxins-10-00042-f001}

![Distribution of differentially expressed genes in turkey. For each comparison, the number of genes with FDR *p*-value \< 0.05 and \|log~2~FC\| \> 2.0 shared or unique to each treatment are indicated in the Venn diagram. Circle size is proportional to the number of genes and direction of expression change (↑ or ↓) is given for the genes in each group.](toxins-10-00042-g002){#toxins-10-00042-f002}

![Distribution of differentially expressed of liver genes between turkey types (Wild and Domesticated). For each comparison, the number of genes with FDR *p*-value \< 0.05 and \|log~2~FC\| \> 2.0 shared or unique to each treatment group are indicated. Circle size is proportional to the number of genes and direction of expression change (↑ or ↓) is given for the genes in each group.](toxins-10-00042-g003){#toxins-10-00042-f003}

![Effect of AFB~1~ on expression of *GSTA3* in the livers of turkeys. (**A**) Mean normalized RNA-seq read counts. For each treatment group, individual read counts are indicated by closed circles. Error bars denote standard deviation of the mean. (**B**) Relative expression as measured by qRT-PCR. For each group the fold change (ΔΔCt) between AFB~1~-treated and control birds is given. Asterisks denote significant comparisons (*p*-value \< 0.01).](toxins-10-00042-g004){#toxins-10-00042-f004}

toxins-10-00042-t001_Table 1

###### 

Summary of RNA-seq data for turkey liver transcriptomes.

  Line               Group      Replicate   PE Reads        Median Read Quality R1   Median Read Quality R2   \% Mapped   \% Concordant   Estimated Insert Mean (bp)   Observed Genes   Expressed Genes   \% Genes Expressed
  ------------------ ---------- ----------- --------------- ------------------------ ------------------------ ----------- --------------- ---------------------------- ---------------- ----------------- --------------------
  **Eastern Wild**   **CNTL**   EW9L        12,148,654      36.5                     36.6                     91.7        86.8            172                          15,857           14,804            70.5
                                EW10L       14,641,781      36.4                     36.5                     90.9        85.7            173                          16,483           14,833            70.6
                                EW12L       11,740,806      36.9                     36.8                     91.1        85.8            191                          16,506           15,448            73.5
                                EW13L       12,466,171      36.9                     36.9                     90.9        85.4            191                          16,572           14,935            71.1
                                **Mean**    12,749,353.0    36.68                    36.70                    91.15       85.93           181.8                        16,354.5         15,005.0          71.4
                     **AFB**    EW1L        11,719,049      36.9                     37.0                     89.7        83.6            192                          17,914           17,073            81.3
                                EW2L        12,615,195      36.9                     37.0                     90.1        84.2            191                          17,911           16,523            78.6
                                EW3L        12,625,962      36.9                     36.9                     90.5        84.7            192                          18,026           17,194            81.8
                                EW4L        12,468,136      36.9                     36.9                     89.9        84.0            193                          18,054           17,230            82.0
                                **Mean**    12,357,085.5    36.90                    36.95                    90.05       84.13           192.0                        17,976.3         17,005.0          80.9
  **Domesticated**   **CNTL**   N11L        12,448,496      36.7                     36.8                     92.4        87.7            172                          15,993           14,837            70.6
                                N12L        12,857,795      36.7                     36.7                     92.3        87.7            172                          16,136           14,399            68.5
                                N13L        11,417,338      37.2                     37.4                     91.4        85.7            212                          16,634           15,584            74.2
                                N14L        12,099,335      36.7                     36.6                     91.9        87.0            170                          15,952           14,780            70.4
                                **Mean**    12,205,741.0    36.83                    36.88                    92.00       87.03           181.5                        16,178.7         14,900.0          70.9
                     **AFB**    N1L         11,388,753      37.2                     37.4                     90.3        84.3            212                          17,967           17,109            81.4
                                N2L         12,827,964      37.1                     37.3                     89.8        83.6            213                          18,083           16,752            79.7
                                N3L         10,821,683      37.1                     37.3                     90.4        84.4            211                          17,903           17,048            81.1
                                N4L         11,144,371      37.2                     37.3                     90.1        84.0            211                          17,989           17,119            81.5
                                **Mean**    11,545,693.0    37.15                    37.33                    90.15       84.08           211.8                        17,985.5         17,007.0          81.0
  **Mean**                                  12,214,468.06   36.89                    36.96                    90.84       85.29           191.75                       17,123.75        15,979.25         76.1

For each library the total number of concatenated reads, median read qualities (R1 and R2), estimated mean insert length (bp), number of and percentage of aligned reads, percentage of concordant reads, and the number and percentage of observed genes (mapped reads \> 1) and expressed genes (mean group normalized read count \> 3.0) are given.

toxins-10-00042-t002_Table 2

###### 

Summary of genes with significant differential expression (DE) in pair-wise comparisons of treatment groups.

  Comparison      Groups              Expressed Genes   Shared Genes   Unique Genes/Group   FDR Pval \< 0.05   \|log~2~FC\| \> 1.0   \|log~2~FC\| \> 2.0
  --------------- ------------------- ----------------- -------------- -------------------- ------------------ --------------------- ---------------------
  AFB~1~ effect   EW (AFB vs. CNTL)   17,342            14,908         2147/287             9620               7168                  4176
                  DT (AFB vs. CNTL)   17,403            14,669         2407/328             11,325             8001                  4621
  Line            CNTL (EW vs. DT)    15,525            14,667         528/330              744                495                   184
                  AFB (EW vs. DT)     17,411            16,719         336/356              903                456                   143

For each comparison, the treatment groups, number of genes with significant FDR *p*-value, and the numbers of significant genes that also had \|log~2~ fold change\| \> 1.0 and \> 2.0 are given.

toxins-10-00042-t003_Table 3

###### 

Summary of PANTHER Overrepresentation Test of the 796 unique differentially expressed (DE) genes in livers of Eastern wild turkeys compared to controls after AFB~1~ exposure.

  Category                                                           *Gallus gallus*---REFLIST Genes (15,789)   Observed Turkey Genes   Expected   over/under   Fold Enrichment   *p*-Value
  ------------------------------------------------------------------ ------------------------------------------ ----------------------- ---------- ------------ ----------------- ----------------
  **GO biological process complete**                                                                                                                                              
    negative regulation of neurogenesis (GO:0050768)                 101                                        12                      2.15       \+           5.58              1.28 × 10^−2^
    negative regulation of cell development (GO:0010721)             119                                        13                      2.53       \+           5.13              1.21 × 10^−2^
    negative regulation of nervous system development (GO:0051961)   111                                        12                      2.36       \+           5.08              3.29 × 10^−2^
    regulation of system process (GO:0044057)                        184                                        16                      3.92       \+           4.09              1.58 × 10^−2^
    regulation of membrane potential (GO:0042391)                    185                                        16                      3.94       \+           4.06              1.69 × 10^−2^
    regulation of neuron differentiation (GO:0045664)                233                                        19                      4.96       \+           3.83              4.83 × 10^−3^
    regulation of neurogenesis (GO:0050767)                          279                                        20                      5.94       \+           3.37              1.72 × 10^−2^
    regulation of nervous system development (GO:0051960)            323                                        23                      6.87       \+           3.35              3.53 × 10^−3^
    neurological system process (GO:0050877)                         337                                        22                      7.17       \+           3.07              2.45 × 10^−2^
    system process (GO:0003008)                                      559                                        30                      11.9       \+           2.52              2.36 × 10^−2^
    generation of neurons (GO:0048699)                               589                                        31                      12.53      \+           2.47              2.40 × 10^−2^
    neurogenesis (GO:0022008)                                        636                                        33                      13.53      \+           2.44              1.57 × 10^−2^
    nervous system development (GO:0007399)                          886                                        44                      18.85      \+           2.33              1.03 × 10^−3^
    regulation of multicellular organismal process (GO:0051239)      1083                                       52                      23.05      \+           2.26              2.01 × 10^−4^
    system development (GO:0048731)                                  1613                                       64                      34.33      \+           1.86              4.44 × 10^−3^
    cell communication (GO:0007154)                                  2250                                       85                      47.88      \+           1.78              3.50 × 10^−4^
    single organism signaling (GO:0044700)                           2201                                       83                      46.84      \+           1.77              5.71 × 10^−4^
    multicellular organismal process (GO:0032501)                    2417                                       91                      51.44      \+           1.77              1.16 × 10^−4^
    signaling (GO:0023052)                                           2205                                       83                      46.92      \+           1.77              6.18 × 10^−4^
    multicellular organism development (GO:0007275)                  1814                                       68                      38.6       \+           1.76              1.37 × 10^−2^
    single-multicellular organism process (GO:0044707)               2120                                       79                      45.11      \+           1.75              2.09 × 10^−3^
    anatomical structure development (GO:0048856)                    1971                                       71                      41.94      \+           1.69              3.16 × 10^−2^
    single-organism process (GO:0044699)                             6098                                       180                     129.77     \+           1.39              1.05 × 10^−4^
    Unclassified (UNCLASSIFIED)                                      6357                                       84                      135.28     \-           0.62              0.00 × 10
  **GO cellular component complete**                                                                                                                                              
    sarcolemma (GO:0042383)                                          43                                         7                       0.92       \+           7.65              4.23 × 10^−2^
    proteinaceous extracellular matrix (GO:0005578)                  168                                        14                      3.58       \+           3.92              1.85 × 10^−2^
    extracellular matrix (GO:0031012)                                249                                        18                      5.3        \+           3.4               8.51 × 10^−3^
    plasma membrane part (GO:0044459)                                987                                        45                      21.0       \+           2.14              1.33 × 10^−3^
    intrinsic component of membrane (GO:0031224)                     3244                                       132                     69.03      \+           1.91              3.19 × 10^−12^
    integral component of membrane (GO:0016021)                      3200                                       129                     68.1       \+           1.89              1.70 × 10^−11^
    plasma membrane (GO:0005886)                                     1834                                       71                      39.03      \+           1.82              4.27 × 10^−4^
    membrane part (GO:0044425)                                       3689                                       142                     78.5       \+           1.81              1.39 × 10^−11^
    cell periphery (GO:0071944)                                      1888                                       72                      40.18      \+           1.79              6.08 × 10^−4^
    extracellular region part (GO:0044421)                           1555                                       57                      33.09      \+           1.72              3.49 × 10^−2^
    membrane (GO:0016020)                                            4745                                       154                     100.98     \+           1.53              7.69 × 10^−7^
    organelle part (GO:0044422)                                      3580                                       45                      76.18      \-           0.59              1.11 × 10^−2^
    intracellular organelle part (GO:0044446)                        3472                                       41                      73.89      \-           0.55              2.59 × 10^−3^
    nucleus (GO:0005634)                                             3106                                       35                      66.1       \-           0.53              3.12 × 10^−3^
    organelle lumen (GO:0043233)                                     1703                                       15                      36.24      \-           0.41              2.45 × 10^−2^
    intracellular organelle lumen (GO:0070013)                       1703                                       15                      36.24      \-           0.41              2.45 × 10^−2^
    membrane-enclosed lumen (GO:0031974)                             1703                                       15                      36.24      \-           0.41              2.45 × 10^−2^
    nuclear part (GO:0044428)                                        1764                                       15                      37.54      \-           0.4               1.01 × 10^−2^
    Unclassified (UNCLASSIFIED)                                      6062                                       78                      129.0      \-           0.6               0.00 × 10
  **GO molecular function complete**                                                                                                                                              
    transporter activity                                             861                                        39                      18.32      \+           2.13              1.71 × 10^−2^
    nucleic acid binding                                             1988                                       15                      42.31      \-           0.35              6.66 × 10^−4^
    Unclassified                                                     6653                                       112                     141.58     \-           0.79              0.00 × 10

Included categories had fold enrichment (number of DE genes divided by expected (Exp)) \> 2.0. For each Gene Ontology category, the number of genes in the reference list and those differentially expressed in the turkey are given. DE turkey genes were matched to the chicken gene reference list for analysis in PANTHER \[[@B38-toxins-10-00042]\]. *p*-values are as determined by the binomial statistic.

toxins-10-00042-t004_Table 4

###### 

Summary of PANTHER Overrepresentation Test of the 1241 unique differentially expressed (DE) genes in liver of domesticated turkeys after AFB~1~ exposure as compared to controls.

  Category                                                *Gallus gallus*---REFLIST Genes (15789)   Observed Turkey Genes   Expected   over/under   Fold Enrichment   *p*-Value
  ------------------------------------------------------- ----------------------------------------- ----------------------- ---------- ------------ ----------------- ----------------
  **GO biological process complete**                                                                                                                                  
    organelle fission (GO:0048285)                        135                                       17                      4.52       \+           3.76              2.53 × 10^−2^
    oxidation-reduction process (GO:0055114)              549                                       46                      18.39      \+           2.50              1.11 × 10^−4^
    regulation of immune system process (GO:0002682)      408                                       33                      13.67      \+           2.41              2.40 × 10^−2^
    signal transduction (GO:0007165)                      2057                                      114                     68.92      \+           1.65              2.19 × 10^−4^
    Signaling (GO:0023052)                                2205                                      122                     73.88      \+           1.65              6.80 × 10^−5^
    single organism signaling (GO:0044700)                2201                                      121                     73.74      \+           1.64              1.15 × 10^−4^
    single-organism metabolic process (GO:0044710)        1745                                      95                      58.47      \+           1.62              8.40 × 10^−3^
    cell communication (GO:0007154)                       2250                                      122                     75.38      \+           1.62              2.13 × 10^−4^
    cellular response to stimulus (GO:0051716)            2657                                      135                     89.02      \+           1.52              1.45 × 10^−3^
    single-organism process (GO:0044699)                  6098                                      309                     204.31     \+           1.51              1.54 × 10^−16^
    response to stimulus (GO:0050896)                     3224                                      159                     108.02     \+           1.47              5.26 × 10^−4^
    single-organism cellular process (GO:0044763)         4263                                      205                     142.83     \+           1.44              1.46 × 10^−5^
    regulation of cellular process (GO:0050794)           4810                                      220                     161.16     \+           1.37              2.08 × 10^−4^
    regulation of biological process GO:0050789)          5131                                      227                     171.91     \+           1.32              1.83 × 10^−3^
    biological regulation (GO:0065007)                    5521                                      244                     184.98     \+           1.32              4.20 × 10^−4^
    cellular process (GO:0009987)                         7267                                      307                     243.48     \+           1.26              1.04 × 10^−4^
    Unclassified                                          6357                                      130                     212.99     \-           0.61              0.00 × 10
  **GO cellular component complete**                                                                                                                                  
    mitochondrial inner membrane (GO:0005743)             213                                       22                      7.14       \+           3.08              4.57 × 10^−3^
    mitochondrial membrane (GO:0031966)                   273                                       26                      9.15       \+           2.84              2.75 × 10^−3^
    mitochondrial envelope (GO:0005740)                   290                                       27                      9.72       \+           2.78              2.69 × 10^−3^
    organelle inner membrane (GO:0019866)                 239                                       22                      8.01       \+           2.75              2.60 × 10^−2^
    mitochondrial part (GO:0044429)                       395                                       30                      13.23      \+           2.27              3.65 × 10^−2^
    mitochondrion (GO:0005739)                            819                                       50                      27.44      \+           1.82              3.85 × 10^−2^
    membrane part (GO:0044425)                            3689                                      193                     123.6      \+           1.56              7.73 × 10^−9^
    cell periphery (GO:0071944)                           1888                                      98                      63.26      \+           1.55              7.45 × 10^−3^
    plasma membrane (GO:0005886)                          1834                                      95                      61.45      \+           1.55              1.15 × 10^−2^
    intrinsic component of membrane (GO:0031224)          3244                                      166                     108.69     \+           1.53              2.94 × 10^−6^
    integral component of membrane (GO:0016021)           3200                                      163                     107.21     \+           1.52              6.18 × 10^−6^
    Membrane(GO:0016020)                                  4745                                      238                     158.98     \+           1.50              3.01 × 10^−10^
    Cell (GO:0005623)                                     7948                                      328                     266.29     \+           1.23              4.09 × 10^−5^
    cell part (GO:0044464)                                7895                                      325                     264.52     \+           1.23              7.49 × 10^−5^
    Intracellular (GO:0005622)                            6948                                      279                     232.79     \+           1.20              3.08 × 10^−2^
    intracellular ribonucleoprotein complex GO:0030529)   437                                       2                       14.64      \-           \<0.20            4.24 × 10^−2^
    ribonucleoprotein complex (GO:1990904)                438                                       2                       14.67      \-           \<0.20            4.12 × 10^−2^
    Unclassified                                          6062                                      115                     203.10     \-           0.57              0.00 × 10
  **GO molecular function complete**                                                                                                                                  
    oxidoreductase activity (GO:0016491)                  486                                       38                      16.28      \+           2.33              3.68 × 10^−3^
    ion binding (GO:0043167)                              3114                                      144                     104.33     \+           1.38              3.63 × 10^−2^
    Unclassified                                          6653                                      155                     222.9      \-           0.70              0.00 × 10

DE turkey genes were matched to the chicken gene reference list for analysis in PANTHER \[[@B38-toxins-10-00042]\]. For each, Gene Ontology category, the number of genes in the reference list and those differentially expressed in the turkey are given. Fold enrichment is the number of DE genes divided by Expected. *p*-values are as determined by the binomial statistic.

toxins-10-00042-t005_Table 5

###### 

Summary of PANTHER Overrepresentation Test of the 136 unique differentially expressed (DE) genes in livers of Eastern wild turkeys after AFB~1~ exposure as compared to domesticated turkey.

  GO Biological Process Complete                                             *Gallus gallus*---REFLIST Genes (15782)   Observed Turkey Genes   Expected   over/under   Fold Enrichment   *p*-Value
  -------------------------------------------------------------------------- ----------------------------------------- ----------------------- ---------- ------------ ----------------- ---------------
    L-serine biosynthetic process (GO:0006564)                               3                                         3                       0.01       \+           \>100             6.60 × 10^−4^
    blood coagulation, fibrin clot formation (GO:0072378)                    5                                         3                       0.02       \+           \>100             3.04 × 10^−3^
    plasminogen activation (GO:0031639)                                      5                                         3                       0.02       \+           \>100             3.04 × 10^−3^
    positive regulation of heterotypic cell-cell adhesion (GO:0034116)       6                                         3                       0.02       \+           \>100             5.24 × 10^−3^
    L-serine metabolic process (GO:0006563)                                  6                                         3                       0.02       \+           \>100             5.24 × 10^−3^
    zymogen activation (GO:0031638)                                          9                                         4                       0.03       \+           \>100             1.15 × 10^−4^
    regulation of heterotypic cell-cell adhesion (GO:0034114)                9                                         3                       0.03       \+           \>100             1.76 × 10^−2^
    fibrinolysis (GO:0042730)                                                9                                         3                       0.03       \+           \>100             1.76 × 10^−2^
    negative regulation of endothelial cell apoptotic process (GO:2000352)   11                                        3                       0.03       \+           87.84             3.20 × 10^−2^
    neg regulation of ext apoptotic signaling pathway (GO:1902042)           11                                        3                       0.03       \+           87.84             3.20 × 10^−2^
    positive regulation of vasoconstriction (GO:0045907)                     12                                        3                       0.04       \+           80.52             4.14 × 10^−2^
    positive regulation of peptide hormone secretion (GO:0090277)            30                                        4                       0.09       \+           42.94             1.36 × 10^−2^
    cell-matrix adhesion (GO:0007160)                                        44                                        5                       0.14       \+           36.6              1.52 × 10^−3^
    coagulation (GO:0050817)                                                 65                                        5                       0.20       \+           24.78             1.02 × 10^−2^
    blood coagulation (GO:0007596)                                           65                                        5                       0.20       \+           24.78             1.02 × 10^−2^
    cell-substrate adhesion (GO:0031589)                                     66                                        5                       0.20       \+           24.4              1.10 × 10^−2^
    hemostasis (GO:0007599)                                                  66                                        5                       0.20       \+           24.4              1.10 × 10^−2^
    positive regulation of protein secretion (GO:0050714)                    69                                        5                       0.21       \+           23.34             1.36 × 10^−2^
    positive regulation of peptide secretion (GO:0002793)                    78                                        5                       0.24       \+           20.65             2.46 × 10^−2^
    alpha-amino acid metabolic process (GO:1901605)                          104                                       6                       0.32       \+           18.58             4.71 × 10^−3^
    regulation of response to external stimulus (GO:0032101)                 264                                       8                       0.82       \+           9.76              7.87 × 10^−3^
    small molecule metabolic process (GO:0044281)                            816                                       13                      2.53       \+           5.13              4.46 × 10^−3^
    single-organism metabolic process (GO:0044710)                           1775                                      19                      5.51       \+           3.45              3.17 × 10^−3^
    single-organism process (GO:0044699)                                     6214                                      39                      19.29      \+           2.02              5.62 × 10^−5^
    Unclassified (UNCLASSIFIED)                                              6196                                      6                       19.24      \-           0.31              0.00 × 10

DE turkey genes were matched to the chicken gene reference list for analysis in PANTHER \[[@B38-toxins-10-00042]\]. For each, Gene Ontology category, the number of genes in the reference list and those differentially expressed in the turkey are given. Fold enrichment is the number of DE genes divided by Expected. *p*-values are as determined by the binomial statistic.

toxins-10-00042-t006_Table 6

###### 

Differential expression (DE) of genes from major enzyme groups responsible for metabolizing xenobiotic chemicals.

  ID               EW AFB vs. CNTL   DT AFB vs. CNTL   CNTL EW vs. DT   AFB EW vs. DT   Description                                
  ---------------- ----------------- ----------------- ---------------- --------------- ------------- --------- -------- --------- -------------------------------------------------------------------------
  *AKR1D1*         0.9964            0.0559            0.0000           −2.6518         0.0000        −3.2445   0.2276   −0.5988   aldo-keto reductase family 1, member D1
  *ALDH2*          0.0190            −0.8404           0.0000           −1.5779         0.1522        −0.5354   0.9648   0.1539    aldehyde dehydrogenase 2 family (mitochondrial)
  *AOX1*           0.0000            2.1137            0.0010           0.8410          0.0574        −0.6975   0.2037   0.5258    aldehyde oxidase 1
  *COMT*           0.0000            −2.5729           0.0000           −2.8723         0.0373        −0.7682   0.2064   −0.5319   catechol-*O*-methyltransferase
  ***CYP1A5***     0.0000            −6.0043           0.0000           −9.2792         0.0721        −0.8105   0.0000   2.4042    cytochrome P450, family 1, subfamily A, polypeptide 5
  ***CYP3A37***    0.0640            −0.9576           0.0000           −2.8884         0.0007        −1.5099   0.8268   0.3698    cytochrome P450 3A37
  *CYP3A80*        0.9731            −0.1270           0.0052           −1.0866         0.0022        −1.7031   0.3001   −0.8022   cytochrome P450 3A80
  *EPHX1*          0.0000            3.0994            0.0007           0.9636          0.2271        −0.8719   0.0009   1.2112    epoxide hydrolase 1, microsomal (xenobiotic)
  *EPHX2*          0.0000            −2.7512           0.0000           −2.5788         0.4757        0.4301    0.8342   0.2075    epoxide hydrolase 2, cytoplasmic
  *EPHX4*          0.0000            3.1365            0.0091           2.4479          1.0000        0.3859    0.1409   1.0154    epoxide hydrolase 4
  *GSTA1.1* \*     0.0000            −2.0007           0.0000           −2.6584         0.0066        1.3021    0.0000   1.9010    glutathione *S*-transferase alpha class A1.1
  *GSTA1.3* \*     0.0004            −1.0804           0.0000           −1.6746         0.1740        0.6098    0.0003   1.1419    glutathione *S*-transferase alpha class A1.3
  *GSTA2*          0.0000            −1.7332           0.0000           −1.9211         0.1019        0.5386    0.0098   0.6713    glutathione *S*-transferase 2
  ***GSTA3***      0.8469            0.1297            0.0014           1.4667          0.0000        2.3130    0.0063   0.9211    glutathione *S*-transferase 3
  ***GSTA4***      0.0000            −5.9578           0.0000           −6.4058         0.3086        0.5690    0.0204   0.9569    glutathione *S*-transferase 4
  *GSTK1*          0.0000            −1.8072           0.0000           −2.9850         0.1814        −0.5583   0.0773   0.5713    glutathione *S*-transferase kappa 1
  *GSTZ1*          0.0000            −3.3639           0.0000           −4.1131         1.0000        0.0517    0.0325   0.7477    glutathione *S*-transferase zeta 1
  *LOC100538434*   0.0000            1.7178            0.7570           0.1451          0.0038        −0.9746   0.3530   0.5480    cytochrome P450 4B1-like
  *LOC100538440*   0.0000            −2.8970           0.0000           −2.2682         0.1163        0.5550    0.9682   −0.1256   glutathione *S*-transferase theta-1-like
  *LOC100538588*   0.0025            −1.1881           0.0000           −3.4884         0.0001        −1.2845   0.0758   0.9622    cytochrome P450 4B1-like
  *LOC100538595*   0.0000            −7.0046           0.0000           −8.5660         1.0000        0.0523    0.1895   1.5495    glutathione *S*-transferase theta-1
  *LOC100542486*   0.0000            −3.3050           0.0000           −7.4005         0.1187        −0.8954   0.0000   3.1496    cytochrome P450 1A4
  *LOC100543147*   0.0000            −1.9129           0.0001           −1.0244         0.0097        0.8235    0.9927   −0.1181   cytochrome P450 2U1
  *LOC100543474*   0.0000            4.4089            0.0000           3.2044          0.6256        −0.4228   0.0227   0.7294    glutathione *S*-transferase omega-1-like
  *LOC100544448*   0.0000            −3.1080           0.0000           −3.1865         1.0000        −0.1757   1.0000   −0.1579   cytochrome P450 2C9-like
  *LOC100544938*   0.0000            −1.6254           0.0052           −0.8255         0.8684        0.3729    0.3538   −0.4894   cytochrome P450 26B1
  *LOC100545163*   0.0000            −2.7394           0.0000           −3.5785         0.0404        −0.7668   1.0000   0.0207    alcohol dehydrogenase 1
  *LOC100545251*   0.0055            −0.8765           0.0000           −1.7618         0.6466        0.3201    0.0085   1.1514    sulfotransferase 1C1-like
  *LOC100545313*   0.0011            −6.6206           0.0000           −12.9085        0.0662        2.5030    0.0071   9.2625    sulfotransferase 6B1-like
  *LOC100545337*   0.0042            −0.8258           0.4111           0.3711          0.0116        1.3434    1.0000   0.0879    sulfotransferase family cytosolic 2B member 1-like
  *LOC100545469*   0.0000            −7.4792           0.0000           −12.4538        0.8899        −0.3159   0.0330   4.6071    sulfotransferase 6B1-like
  *LOC100545683*   0.0000            −2.4276           0.0000           −5.5488         0.3422        −0.8455   0.0915   2.2195    cytochrome P450 2H1-like
  *LOC100546724*   0.0000            1.8339            0.0095           0.8064          0.1178        −0.9930   1.0000   −0.0121   cytochrome P450 2K4-like
  *LOC100546874*   0.0169            0.7907            0.0000           0.9012          1.0000        0.0100    0.9251   −0.1538   cytochrome P450 2W1-like
  *LOC100547030*   0.0000            −7.6458           0.0000           −13.6234        1.0000        −0.2262   0.0010   5.8718    cytochrome P450 2W1-like
  *LOC100547576*   0.0000            −4.3115           0.0000           −5.2719         0.0014        −1.0131   1.0000   −0.1127   UDP-glucuronosyltransferase 1-1-like
  *LOC100547627*   0.7689            0.1433            0.0094           −0.7229         0.0023        −1.0592   0.7311   −0.2480   sulfotransferase family cytosolic 1B member 1
  *LOC100547794*   0.0284            0.7020            0.9613           0.0689          0.9308        −0.3488   0.7143   0.2327    cytochrome P450 2J2-like
  *LOC100547885*   0.0011            −0.9841           0.0000           −2.4195         0.0453        −0.6672   0.0321   0.7153    UDP-glucuronosyltransferase 1-1-like
  *LOC100548173*   0.0000            3.7249            0.0000           2.5969          1.0000        −0.3391   0.1461   0.7080    galactosylgalactosylxylosylprotein 3-betaglucuronosyltransferase 1-like
  *LOC100548279*   0.0000            −7.9193           0.0000           −11.0735        0.5445        −0.5533   0.0906   2.5242    cytochrome P450 2K4-like
  *LOC100548322*   0.0000            −5.6388           0.0000           −7.6409         0.0002        −1.2226   0.0429   0.7206    cytochrome P450 2D17
  *LOC100548433*   0.0000            −5.3627           0.0000           −8.5915         1.0000        −0.1464   0.0000   3.0249    cytochrome P450 2K1-like
  *LOC100548965*   0.0027            1.2412            0.4561           0.2791          0.5805        0.4725    0.0144   1.3798    cytochrome P450 2J3-like
  *LOC100549160*   0.0000            −1.5607           0.0000           −1.7517         0.0335        −0.7103   0.3717   −0.5706   cytochrome P450 4F22
  *LOC100549268*   0.0000            2.8734            0.0067           1.6835          1.0000        −0.3799   0.2658   0.7421    aldehyde oxidase 2-like
  *LOC100549312*   0.3177            0.3574            0.0000           −1.5738         0.0000        −1.9158   1.0000   −0.0363   UDP-glucuronosyltransferase 2C1-like
  *LOC100549991*   0.0000            −1.7655           0.0000           −1.6943         0.0002        1.3894    0.0039   1.2611    arylamine *N*-acetyltransferase, liver isozyme
  *LOC100550430*   0.0512            −0.6659           0.0000           −1.3736         0.2945        −0.4855   0.9495   0.1737    cytochrome P450 4F22
  *LOC104909216*   0.0925            3.6677            0.0207           4.6262          1.0000        0.0000    0.5908   −1.0481   cytochrome P450 2J6-like
  *LOC104909734*   0.0000            −6.4443           0.0023           −2.1011         0.0000        4.1441    1.0000   −0.2356   sulfotransferase family cytosolic 2B member 1-like
  *LOC104910746*   0.0000            −3.6385           0.0000           −5.1988         0.7764        −0.3620   0.1896   1.1405    alcohol dehydrogenase 1-like
  *LOC104911955*   0.3696            −0.4051           0.0000           −1.7954         0.0045        −1.2985   1.0000   0.0458    cytochrome P450 2H2
  *LOC104912373*   0.0000            6.1224            0.0000           7.7909          0.2163        2.2765    0.2724   0.5912    sulfotransferase 6B1-like
  *LOC104912427*   0.0001            0.8626            0.0006           0.8049          0.7651        −0.3468   0.3464   −0.3463   cytochrome P450 2J2-like
  *LOC104912428*   0.1738            0.5765            1.0000           0.0281          0.2879        0.5209    0.0401   1.0161    cytochrome P450 2J2-like
  *LOC104912494*   0.0006            1.5962            0.0373           0.5871          1.0000        −0.1563   0.3537   0.7988    cytochrome P450 2J2-like
  *LOC104915391*   0.0000            −4.4041           0.0000           −4.5429         1.0000        0.2453    0.9573   0.3281    sulfotransferase family cytosolic 2B member 1-like
  *LOC104915445*   0.0000            −3.6108           0.0000           −4.2325         0.0262        −0.8559   0.9682   −0.2891   alcohol dehydrogenase 1-like
  *LOC104915446*   0.0000            −3.8678           0.0000           −5.4661         0.1525        −0.6518   0.4129   0.8857    alcohol dehydrogenase 1-like
  *LOC104915473*   0.0000            1.5141            0.8643           0.0874          0.8777        −0.3084   0.0010   1.0674    UDP-glucuronosyltransferase 1-9-like
  *LOC104915474*   0.8756            −0.1560           0.0000           −3.7112         0.0000        −2.5312   0.0418   0.9617    UDP-glucuronosyltransferase 1-6-like
  *LOC104915476*   0.0006            1.6704            0.9112           0.1504          0.4764        −1.0151   0.6292   0.4445    UDP-glucuronosyltransferase 1-1-like
  *LOC104915477*   0.0000            −4.3026           0.0000           −6.1630         1.0000        0.0675    0.0160   1.8961    UDP-glucuronosyltransferase 1-6 pseudogene
  *LOC104915478*   0.0000            −1.7304           0.0000           −3.7892         1.0000        0.1939    0.0017   2.2036    UDP-glucuronosyltransferase 1-1-like
  *LOC104915479*   0.0000            −2.4027           0.0000           −5.5537         0.1838        −0.9621   0.0384   2.1351    cytochrome P450 2H1-like
  *LOC104915586*   0.0000            −5.9323           0.0090           −2.7687         0.0023        3.1518    1.0000   −0.0267   sulfotransferase family cytosolic 2B member 1-like
  *LOC104915609*   0.0022            −3.8661           0.0686           −3.9012         0.8037        1.2048    1.0000   1.5781    cytochrome P450 2C19-like
  *LOC104915610*   0.0000            3.8631            0.0000           3.5278          0.9437        −0.6231   0.9255   −0.3368   cytochrome P450 2C4-like
  *LOC104916399*   0.0000            −6.0701           0.0000           −7.5516         0.5648        0.6141    0.4295   2.0569    cytochrome P450 2C27-like
  *LOC104916553*   0.0000            −4.9703           0.0000           −3.9795         0.5369        0.6853    0.9367   −0.3716   sulfotransferase family cytosolic 2B member 1-like
  *LOC104916909*   0.0000            −5.6085           0.0000           −7.0458         0.5315        0.5373    0.1227   1.9411    cytochrome P450 2C31-like
  *NQO1*           0.7812            −0.1408           0.0008           −0.8283         1.0000        −0.1435   0.2145   0.4945    NAD(P)H dehydrogenase, quinone 1
  *NQO2*           0.0000            −0.9071           0.4267           −0.2242         0.4389        0.3990    0.5130   −0.3430   NAD(P)H dehydrogenase, quinone 2
  *PTGS1*          0.0000            1.4444            0.1729           0.5413          0.9517        −0.4782   0.5266   0.3552    prostaglandin-endoperoxide synthase 1
  *PTGS2*          0.7963            0.1315            0.0000           1.3365          0.1157        0.7544    0.1495   −0.5069   prostaglandin-endoperoxide synthase 2
  *SULT4A1*        0.1141            −0.6315           0.0039           −0.8113         1.0000        0.3027    0.4515   0.4192    sulfotransferase family 4A, member 1
  *SULT6B1*        0.0457            −1.6954           0.0001           −2.6041         1.0000        0.0540    0.7545   0.9577    sulfotransferase family, cytosolic, 6B, member 1
  *TPMT*           0.9701            0.0725            0.0017           −0.7106         0.8466        −0.2968   0.2312   0.4402    thiopurine S-methyltransferase
  *UGT8*           0.0000            1.7926            0.0000           1.1497          0.5752        −0.3194   0.6356   0.2705    UDP glycosyltransferase 8

Genes included were significant (FDR *p*-value \< 0.05) in at least one comparison. Comparisons highlighted in green are down regulated and those in red up regulated. Cytochrome P450 (CYP) and glutathione S-transferase (GST) family members shown to have *in vitro* activity towards AFB~1~ and its metabolites in turkey are indicated in bold. \* Due to similarity, these likely include transcripts assignable to *GSTA1.1*, *A1.2*, and *A1.3*.
